Introduction {#S1}
============

Bacterial resistance has been a global public health concern ([@B32]; [@B4]). Currently, Gram-negative bacteria are developing multidrug resistance and broad-spectrum drug resistance, and the available antibiotics used in clinical treatment, agricultural and livestock production are gradually decreasing ([@B1]; [@B37]). Polymyxins and carbapenems are among the antibiotics of last resort to treat Gram-negative bacteria infections. In 2009 and 2016, the superbug that carried the New Delhi metallo-beta-lactamase gene (*bla*~NDM--1~) ([@B48]; [@B21]) and the *Escherichia. coli* that carried the colistin resistance gene (*mcr-1*) ([@B27]) were identified. Until now, 9 subtypes of *mcr* ([@B27]; [@B44]; [@B3]; [@B6]; [@B8]; [@B47]; [@B42]; [@B46]; [@B9]) and 21 subtypes of *bla*~NDM~ ([@B24]) have been published with papers. The discovery of these two types of resistance genes that can be horizontally transferred via plasmids has made researchers aware of the post-antibiotic era. Such plasmids usually carry other resistance genes, encoded for aminoglycosides and quinolones for instance ([@B7]; [@B36]). The rapid horizontal spread of drug-resistant genes by plasmids is one of the reasons for the increasing number of multidrug resistant bacteria, however, the transfer range of bacteria species is unknown. Studies have confirmed that many countries and regions have isolated Gram-negative bacteria with *mcr-1* gene ([@B16]; [@B17]; [@B25]), the *bla*~NDM--1~ gene ([@B43]; [@B31]; [@B50]; [@B2]; [@B30]; [@B35]; [@B49]), or both ([@B53]; [@B26]; [@B41]), from humans, the environment and animals. Whether isolates from antibiotics-free and depopulated areas, wildlife, carried *mcr* or *bla*~NDM~ genes is undiscovered.

To explore the transfer range of polymyxins and carbapenems resistance genes, 12,858 Gram-negative isolates of ≥118 species were retrospectively collected. Considering limited genes can be screened for the 12,858 isolates, only the *mcr-1* and *bla*~NDM~ genes were chosen, for their wide dissemination around the world and across species ([@B28]). To confirm the effect of antibiotics on the emergence of resistant strains, strains isolated from wildlife, patients, livestock, poultry, and environment from past 10 years were screened. Strains positive with either of the gene were confirmed by open reading frame (ORF) sequencing, and were tested for antimicrobial susceptibility.

Materials and Methods {#S2}
=====================

Bacteria Isolation and Identification {#S2.SS1}
-------------------------------------

We retrospectively collected 12,858 Gram-negative bacteria that were isolated from wildlife (6,226/12,858), patients (5,828/12,858), livestock and poultry (712/12,858), and environment (92/12,858) in 14 provinces (Anhui, Beijing, Gansu, Guangxi, Guizhou, Hainan, Hunan, Jiangxi, Ningxia, Qinghai, Sichuan, Tianjin, Yunnan, Zhejiang) of China from 2010 to 2019. The study was approved by the ethics review committee of the National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. Informed consent was obtained from participants. All strains were identified using VITEK II Compact system (bioMérieux, France) or API 20E strips (bioMérieux, France). The *mcr-1* or *bla*~NDM~ gene positive strains were identified again by VITEK II Compact system (bioMérieux, France), the results of which were consistent with the original ones.

Screening and ORF Sequencing of *mcr-1* or *bla*~NDM~ Positive Strains {#S2.SS2}
----------------------------------------------------------------------

DNA templates were extracted by using TIANamp Bacteria DNA Kit. Positive controls were used for PCR. All 12,858 Gram-negative bacteria were screened for *mcr-1* and *bla*~NDM~ gene by screening primers ([Table 1](#T1){ref-type="table"}), and ORF of positive strains were further amplified, cloned and sequenced. The *mcr-1* or *bla*~NDM~ positive strains were confirmed only if ORF sequences were obtained.

###### 

The primers for screening and ORF amplification of the *mcr-1* and *bla*~NDM~ genes.

  Primer           Sequence (5′ → 3′)     Product size (bp)   Annealing temperature (°C)
  ---------------- ---------------------- ------------------- ----------------------------
  ***mcr-1***                                                 
  MCR-1_CLR5-F     CGGTCAGTCCGTTTGTTC     309^a^              54
  MCR-1_CLR5-R     CTTGGTCGGTCTGTAGGG                         
  ***bla*~NDM~**                                              
  NDM-1_17U-F      CAGCACACTTCCTATCTC     292^a^              54
  NDM-1_17U-R      CCGCAACCATCCCCTCTT                         
  ***mcr-1***                                                 
  *mcr-1* FL-F     AGAAGCACTGGGTGTAGAAT   2189^b^             54
  *mcr-1* FL-R     GCCATGACAAGAGCGATA                         
  ***mcr-1***                                                 
  FR-*mcr*-FL-F    CATCAATCAGTGGAGCG      2060^b^             54
  FR-*mcr*-FL-R    CTCATCTCAGCAAGTAGG                         
  ***mcr-1***                                                 
  DR-*mcr*-FL-F    GCAGTATAATTGCCGTAA     1841^b^             50
  DR-*mcr*-FL-R    CTGACTGTGCTCAAGGGT                         
  ***bla*~NDM~**                                              
  21U-FL-F         TCGCATAAAACGCCTCTG     1007^b^             54
  21U-FL-R         GAAACTGTCGCACCTCAT                         

a

Screening,

b

ORF amplification.

Antimicrobial Susceptibility Testing {#S2.SS3}
------------------------------------

The minimum inhibitory concentrations (MICs) of polymyxins (polymyxin B and colistin) and carbapenems of 70 strains with *mcr-1* and 6 strains with *bla*~NDM~ were determined by broth microdilution method in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines ([@B13]). Replication of sensitivity testing was conducted. Quality controls and breakpoints were in accordance with the [@B14] and the [@B13] for polymyxins and carbapenems, respectively.

Results {#S3}
=======

Distribution of *mcr-1* or *bla*~NDM~ Positive Strains {#S3.SS1}
------------------------------------------------------

A total of 70 strains with *mcr-1* and 6 strains with *bla*~NDM~ were confirmed. *mcr-1* positive strains were isolated each year since 2012. The positive rate from 2012 to 2019 was 0.31% (2/649), 0.09% (1/1,169), 0.63% (7/1,105), 0.36% (9/2,520), 0.64% (34/5,334), 0.28% (4/1,420), 2.12% (9/424), and 8.16% (4/49), respectively. The isolation rates of *bla*~NDM~ positive strains were 0.08% (2/2,520) in 2015, 0.06% (3/5,334) in 2016, and 0.24% (1/424) in 2018 ([Table 2](#T2){ref-type="table"}). Among the 70 strains with *mcr-1*, 36 were isolated from patients, with a positive rate of 0.62% (36/5,828) ([Table 3](#T3){ref-type="table"}). Thirty-five were isolated from diarrheal stool and 1 was from the sputum of an acute-pancreatitis patient. Twenty-nine strains were isolated from livestock and poultry specimens, with a positive rate of 4.07% (29/712), of which 24 isolates were from pig feces and 5 were from chicken feces. Five strains were isolated from environmental specimens, related to chicken slaughter, with a positive rate of 5.43% (5/92). Six *bla*~NDM~ positive strains were isolated from stool specimens of diarrhea patients, with a positive rate of 0.10% (6/5,828). None of the strains isolated from wild animal specimens were *mcr-1* or *bla*~NDM~ positive, which accounted for 48.42% (6,226/12,858) of all screened strains. These strains were isolated from rodents besides marmots (66.48%, 4,139/6,226), marmots (19.03%, 1,185/6,226), birds (6.10%, 380/6,226), plateau pika (4.34%, 270/6,226) and bats (4.05%, 252/6,226).

###### 

The positive rate of strains with *mcr-1* or *bla*~NDM~ isolated in different years.

          No. *mcr-1* positive strains (%)   No. *bla*~NDM~ positive strain (%)
  ------- ---------------------------------- ------------------------------------
  2010    None                               None
  2011    None                               None
  2012    2 (0.31)                           None
  2013    1 (0.09)                           None
  2014    7 (0.63)                           None
  2015    9 (0.36)                           2 (0.08)
  2016    34 (0.64)                          3 (0.06)
  2017    4 (0.28)                           None
  2018    9 (2.12)                           1 (0.24)
  2019    4 (8.16)                           None
  Total   70 (0.54)                          6 (0.05)

None: no strain positive for the

mcr-1

or

bla

NDM

gene.

###### 

The positive rate of strains with *mcr-1* or *bla*~NDM~ isolated from different sources.

                          No. strains   No. *mcr-1* positive strains (%)   No. *bla*~NDM~ postive strains (%)
  ----------------------- ------------- ---------------------------------- ------------------------------------
  Wildlife                6,226         None                               None
  Livestock and poultry   712           29 (4.07)                          None
  Environment             92            5 (5.43)                           None
  Patients                5,828         36 (0.62)                          6 (0.10)
  Total                   12,858        70 (0.54)                          6 (0.05)

None: no strain positive for the

mcr-1

or

bla

NDM

gene.

Of the *mcr-1* positive strains, 83% were opportunistic or low pathogenic organisms, including 48 strains of *Escherichia coli*, 4 strains of *Escherichia fergusonii*, 1 strain of *Enterobacter cloacae complex*, 1 strain of *Proteus mirabilis*, 1 strain of *Acinetobacter baumannii*, 1 strain of *Kluyvera intermedia*, 1 strain of *Enterobacter aerogenes* and 1 strain of *Citrobacter youngae* ([Figure 1](#F1){ref-type="fig"}). The remaining 17% of the strains were pathogenic strains, including 6 strains of *enteroaggregative Escherichia coli* (EAEC), 3 strains of *enteropathogenic Escherichia coli* (EPEC), 1 strain of *enteroinvasive Escherichia coli* (EIEC), 1 strain of *Salmonella* group and 1 strain of *Shigella sonnei*. Strains carrying the *bla*~NDM~ gene that were low pathogenic or opportunistic organisms were 3 strains of *Escherichia coli*, 2 strains of *Klebsiella pneumoniae ssp. pneumoniae* and 1 strain of *Klebsiella oxytoca*.

![Species and number of *mcr-1* positive strains.](fmicb-11-00121-g001){#F1}

Sequence Analysis of *mcr-1* and *bla*~NDM~ {#S3.SS2}
-------------------------------------------

The sequence alignment of the ORF showed that 68 of 70 *mcr-1* positive strains possessed an identical sequence compared to the reference sequence of the *mcr-1.1* gene, 1626 bp (NCBI Reference Sequence: KP347127, region: 22413-24038) ([Figure 2](#F2){ref-type="fig"}). Among these strains, 65 were resistant while 3 were sensitive to polymyxins. The additional 2 *mcr-1* positive strains had a single base mutation compared to the reference sequence. One possessed *mcr-*1.21 (GenBank: MK965883), an *Escherichia coli* isolated from pig feces in Qinghai in 2016, which mutated at 1234 nt of reference sequence from C to T, resulting in a proline to serine change at the amino acid level. This strain shows resistance to polymyxins. The other strain possessed MK965884, an EAEC isolated from the stool of a diarrhea patient in Beijing in 2012. A base mutation site was located at 1344 nt of the reference sequence from G to A, resulting in a stop codon. The susceptibility results showed sensitivity to polymyxins.

![The nucleotide differences, amino acid differences and information of *mcr-1* positive strains in this study \*NA: not assigned by NCBI. \*\*R: resistant, S:sensitive.](fmicb-11-00121-g002){#F2}

Of 6 *bla*~NDM~ positive strains, 3 had identical sequences compared to the 813 bp reference sequence in the ORF of the *bla*~NDM--1~ gene (NCBI Reference Sequence: FN396876 REGION: 2420-3232), 2 were identical to the *bla*~NDM--3~ gene (NCBI Reference Sequence: JQ734687 REGION: 1-813), and 1 was identical to the 813 bp reference sequence in the ORF of the *bla*~NDM--5~ gene (NCBI Reference Sequence: JN104597 REGION: 115-927).

Antimicrobial Susceptibility Result {#S3.SS3}
-----------------------------------

According to clinical breakpoint of carbapenem antibiotics, CLSI, all 70 strains carrying *mcr-1* showed sensitivity to ertapenem, imipenem, and meropenem. Among the 6 strains with *bla*~NDM~, 5 were resistant to ertapenem (MIC \> 4 μg/ml), imipenem (3 strains MIC \> 4 μg/ml, 2 strains MIC = 4 μg/ml) and meropenem (MIC \> 4 μg/ml), while the other strain was resistant to ertapenem (MIC \> 4 μg/ml) but intermediate to imipenem (MIC = 2 μg/ml) and meropenem (MIC = 2 μg/ml). According to clinical breakpoint of EUCAST, among the 70 strains with the *mcr-1* gene, 66 were resistant to polymyxins (polymyxin B: 6 strains MIC = 4 μg/ml, 33 strains MIC = 8 μg/ml, 27 strain MIC \> 8 μg/ml. colistin: 9 strains MIC = 4 μg/ml, 47 strains MIC = 8 μg/ml, 10 strain MIC \> 8 μg/ml) and the other four were sensitive to polymyxins (polymyxin B: 3 strains MIC = 1 μg/ml, 1 strain MIC = 0.5 μg/ml. colistin: 4 strains MIC = 0.5 μg/ml) ([Table 4](#T4){ref-type="table"}). Six strains with *bla*~NDM~ were sensitive to polymyxins ([Figure 3](#F3){ref-type="fig"}). The sensitivity data for all strains referred to [Supplementary Table S1](#SM1){ref-type="supplementary-material"}.

###### 

Strain information and MIC values of polymyxins sensitive strains.

                   Bacteria                   Host               Source   Year   *mcr-1* accession number   Polymyxin B MICs (μg/ml)   Colistin MICs (μg/ml)
  ---------------- -------------------------- ------------------ -------- ------ -------------------------- -------------------------- -----------------------
  QHXN2016-F75-2   *Escherichia coli*         Pig                Feces    2016   NG_050417                  1                          0.5
  QHXN2016-F78-2   *Escherichia coli*         Pig                Feces    2016   NG_050417                  1                          0.5
  GX1400471211     *Enterobacter aerogenes*   Diarrhea patient   Stool    2015   NG_050417                  1                          0.5
  CY307223         *Escherichia coli*         Diarrhea patient   Stool    2012   MK965884                   0.5                        0.5

![MICs distribution of carbapenem antibiotics and polymyxins in *mcr-1* and *bla*~NDM~ gene carriers MIC values (≤ 0.06 ∼\>4 μg/ml)\* in regard to ertapenem, imipenem, and meropenem. MIC values ≤0.125 ∼\>8 μg/ml in regard to polymyxin B and colistin.](fmicb-11-00121-g003){#F3}

Discussion {#S4}
==========

The increase in Gram-negative bacterial strains carrying the *mcr* or *bla*~NDM~ genes has led global health workers to reconsider infections and the treatment of bacteria infection ([@B21]). A total of 12,858 strains from ≥118 species of Gram-negative bacteria were screened, only to find 10 species carrying the *mcr-1* gene and 3 species carrying *bla*~NDM~ gene, indicating the species carrying these two genes and interspecific transfer of the two resistance genes were limited. The bacteria carrying these two resistance genes were mainly normal flora of opportunistic or low pathogenic organisms. Bacterial resistance is an ecological feature to maintain the lineage extension of the bacteria. The emergence of drug-resistant strains has a relationship with the widespread use of antibiotics ([@B27]). In fact, drug-resistant strains have existed for a long time ([@B18]). Our study shows that the use of antibiotics may change the number of resistant strains, but it does not have an essential effect on the frequency of gene transfer. For example, metallo-β-lactamases itself is crucial in defining bacterial host specificity. The wider dissemination of NDM among different bacterial hosts, compared to VIM-2 and SPM-1, is mainly due to unique and singular features of this protein ([@B28]). In Gram-positive pathogens, the emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA) were alarming ([@B11]). However, as of May 2015, only 14 VRSA infections have been reported in patients from the United States ([@B39]).

The total detection rate of this study was lower than other studies, mainly because 48.42% (6,226/12,858) of the strains were isolated from wildlife, while neither *mcr-1* nor *bla*~NDM~ genes was positive. Among the wildlife, marmots, plateau pika and bats live away from humans in this study. Rodents besides marmot (such as *Rattus flavipectus* and *Rattus norvegicus*) and birds mainly live between human surroundings and lands away from humans. The existence of antibiotic selective pressure away from humans is minimal, where no strain was found carrying *mcr-1* or *bla*~NDM~ gene. Among other sources, the highest detection rate of *mcr-1* was found in strains from the environment, which related to chicken slaughter (5.43%, 5/92), followed by livestock and poultry (4.07%, 29/712). Colistin has been used as a feed additive for livestock and poultry for growth promotion and disease prevention, especially for the treatment of gastrointestinal infections in livestock and poultry ([@B10]), which may cause widespread resistance of strains in livestock and poultry, further resulting in pollution of the environment, food, water and so on. The *mcr-1* gene was detected in bacteria isolated from imported chickens in Denmark ([@B19]), food ([@B22]; [@B45]) and wastewater ([@B51]; [@B52]) in China. In patients, the strains carrying the *mcr-1* gene (0.62%, 36/5,828) or *bla*~NDM~ gene (0.10%, 6/5,828) are possibly related to the use of polymyxins or carbapenems in hospitals and in-hospital transmission of drug-resistant strains. Therefore, it is possible that the increase in these two kinds of resistant strains is mainly due to the use of polymyxins or carbapenems antibiotics.

Different antibiotics usage may lead to various isolates selection. No resistant strains in this study co-harbored *mcr*-1 and *bla*~NDM--1~ gene, while in other studies from China, such strains were seen ([@B53]; [@B26]; [@B41]). For instances, in patients, different antibiotics treatment were adopted according to different illness and severity. For livestock and poultry, antibiotics usage may also varied with breeding scales and farms. In addition to *mcr-1* and *bla*~NDM--1~ gene, other genotype combination were also reported from China ([@B20]; [@B26]; [@B12]; [@B40]; [@B41]). The *mcr* and *bla*~NDM~ genes co-harbored isolates from China are often *E. coli*., and *E. cloacae*, etc., occasionally. Further restrictions should be made on antibiotics usage for relevant occasions.

Compared with the ORF of the *mcr-1.1* gene, it was found that two strains have variants. One variant *mcr-*1.21 (GenBank: MK965883), changed from C to T at locus 1234 nt, which changed the codon from proline to serine but did not affect the polymyxin-resistant phenotype of the strain. The other variant (GenBank: MK965884) changed from G to A at locus 1344 nt, resulting in a codon change from tryptophan to stop codon. Strain of this variant was sensitive to polymyxins. It was speculated that the translation of this *mcr-1 gene* was terminated when containing premature stop codon and the functional *mcr-1* protein was not completely expressed, it truncated MCR family phosphoethanolamine -- lipid A transferase. These two strains were isolated from pig and diarrhea patients, respectively, implying that mutations may be in response to antibiotic selection and certain environmental stresses. Some researchers have also detected variants of the *mcr-1* gene from bacteria isolated in environment or healthy individuals ([@B29]). In addition, three strains with the *mcr-1* gene were found to be sensitive to polymyxins, suggesting that the gene does not play a role in certain strains ([@B34]), which may be related to the metabolism of the strains. Another possible mechanism is the inhibition of *mcr-1* gene expression or the inactivation of phosphoethanolamine transferase it encodes ([@B23]). In addition, multiple primers were designed to amplify the ORF of *mcr-1* positive strains, indirectly reflecting that the flanking regions of the ORF in this study may be variable. Variations did existed in the upstream of the ORF, compared with reference plasmid (KP347127): sequences amplified by the primer *mcr-1* FL showed T to C mutation at 22377nt. As to sequences amplified by primer FR-*mcr*-FL, shortly after the forward primer (KP347127:22091-22107) was a homologous fragments of ≥256 bp, which should be located at 20897-21152 of KP347127, prior to the location of forward primer.

Many genes are responsible and important for polymyxins or carbapenems resistance, e.g., *bla*~OXA~ ([@B15]) and *bla*~KPC~ ([@B33]). To focus on both mobile and widespread genes, only *mcr-1* and *bla*~NDM~ genes were screened for 12,858 strains, which is on the other hand, the limitation of the study. There may exist other important resistance mechanisms or genes in our strains. We would further resolve it using strains in this study and isolated afterward. The none detection of wildlife isolates from depopulated areas, in sharp contrast with positive findings of isolates from antibiotics-using areas, emphasized the importance of antibiotics management. On the other hand, the majority of strains collected from wildlife and patients is also the limitation of the study and should be considered when making conclusion.

The *mcr-1* and *bla*~NDM~ genes, mainly encoded by plasmids ([@B21]; [@B27]), have caused harm to livestock, poultry, humans and the environment, and therefore active measures should be taken against the bacteria. Our study have demonstrated that the transfer of *mcr-1* or *bla*~NDM~ genes between bacteria may be limited in China, however, the emergence of and increase in polymyxins and carbapenem-resistant strains was mainly related to the selective pressure of antibiotics. When using polymyxins and carbapenems antibiotics for disease prevention and control in the clinical setting, poultry, livestock and environment, strict management of usage is essential ([@B38]; [@B5]), to prevent further intra- and interspecies dissemination of resistance genes and to control the spread of a broad-spectrum drug resistant or multidrug resistant bacteria.
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